AWM
LXEO icon

Avior Wealth Management’s Lexeo Therapeutics LXEO Stock Holding History

Avior Wealth Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-185
Closed -$1.22K – 1664
2024
Q4 		$1.22K Buy
185
+11
+6% +$87 ﹤0.01% 2182
2024
Q3 		$1.57K Buy
+174
New +$2.08K ﹤0.01% 2016

Other funds holding LXEO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Avior Wealth Management's LXEO Position: Q1 2025 in Review

Avior Wealth Management sold out of Lexeo Therapeutics (LXEO) in Q1 2025, closing a stake of 185 shares — an estimated $1.22K sold.

Avior Wealth Management first reported a position in LXEO in Q3 2024 and held it in 2 quarters. The position peaked at $1.57K in Q3 2024. 88 funds tracked by Wall St. Rank hold LXEO as of Q1 2025.

  • Avior Wealth Management reported no remaining Lexeo Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Avior Wealth Management sold 185 Lexeo Therapeutics shares in Q1 2025, an estimated $1.22K.
  • Avior Wealth Management first reported a position in Lexeo Therapeutics in Q3 2024 and held it in 2 quarters.
  • Avior Wealth Management's Lexeo Therapeutics position peaked at $1.57K in Q3 2024.
  • 88 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2025.

Based on Avior Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.